Acute graft-versus-host disease (aGVHD) is a major complication following allogeneic bone marrow transplantation (BMT). Recently, accumulating evidence indicates that the Fas/Fas ligand (FasL) system is implicated in the pathogenesis of aGVHD in murine models. We determined the serum levels of soluble FasL (sFasL) in BMT recipients using an enzyme-linked immunosorbent assay. The serum sFasL was suppressed during the period of myelosuppression following the preparative regimen and subsequently increased with hematopoietic reconstitution after BMT. In patients with aGVHD, the serum sFasL level was significantly higher than in those without aGVHD. In the mixed lymphocyte reaction assay, sFasL in the supernatants was increased with a significant correlation to the level of 3 H-thymidine uptake. Our findings suggest that the Fas/FasL system is activated by allogeneic stimulation and may have close correlation to the development of aGVHD in human BMT. Keywords: bone marrow transplantation; graft-versushost disease; Fas; soluble Fas ligand Allogeneic bone marrow transplantation (BMT) is a clinical treatment modality for a variety of hematologic diseases. Acute graft-versus-host disease (aGVHD) remains a main complication following BMT. The host-reactive T cells play a major role in the pathogenesis of GVHD, proven not only by studies of experimental murine BMT models but also by several clinical studies.
Allogeneic bone marrow transplantation (BMT) is a clinical treatment modality for a variety of hematologic diseases. Acute graft-versus-host disease (aGVHD) remains a main complication following BMT. The host-reactive T cells play a major role in the pathogenesis of GVHD, proven not only by studies of experimental murine BMT models but also by several clinical studies. 1, 2 However, the precise mechanism of the development of tissue damage associated with aGVHD has not been clarified.
Fas (Apo-1, CD95) is a member of the tumor necrosis factor (TNF) receptor family and transmits an apoptotic cell death signal upon ligation with Fas ligand (FasL). 3 Fas is expressed in target tissues of aGVHD including the skin, liver and intestine. 4 The involvement of the Fas/FasL system in the development of aGVHD has been demonstrated in murine BMT models. [5] [6] [7] [8] Recipients transplanted from allogeneic FasL-defective mice exhibited less symptoms of aGVHD compared with those transplanted from allogeneic normal mice. 5 However, little information is available about the involvement of the Fas/FasL system in complications associated with human BMT.
FasL is released from the T cell surface by metalloproteinase-mediated processing. 9 The soluble FasL (sFasL) is increased in the sera of some patients with large granular lymphocytic leukemia and natural killer cell lymphoma. 10 In the present study, we examined the serum sFasL levels in BMT recipients using the enzyme-linked immunosorbent assay (ELISA) to evaluate the implication of sFasL in clinical aGVHD.
Patients and methods

Patients and sera samples
We retrospectively analyzed sera from 21 BMT recipients transplanted between June 1995 and November 1997. There were 17 males and four females with a median age of 33.0 years (range 17-47 years). Nine patients with chronic myelogenous leukemia, five with acute lymphoblastic leukemia, four with acute myeloblastic leukemia, two with myelodysplastic syndrome, and one with severe aplastic anemia were included. Fourteen patients were transplanted from HLA-identical siblings, three from one-locus-mismatched related donors, and four from HLA-matched unrelated donors. Preparative regimens among the cases were various. GVHD prophylaxis was performed with cyclosporin A and short-course methotrexate. Four patients received methylprednisolone at the dose of 2 mg/kg for grades II-IV aGVHD. Serum samples obtained at several points after BMT were subjected to ELISA.
Enzyme-linked immunosorbent assay for human FasL
Two monoclonal antibodies against human FasL, F918-20-2 and F919-9-18, were prepared previously (manuscript in preparation). Ninety-six-well plates (Maxisorb, Nunc, New York, USA) were coated with the F918-20-2 antibody. One hundred l of the five-fold diluted sera samples were added to the wells and incubated for 2 h at 37°C. Subsequently, the wells were washed with saline containing 0.05% Tween 20 and incubated with poly peroxidase-labeled F919-9-18 antibody for 1 h at 37°C, washed five times with saline containing 0.05% Tween 20, washed twice with distilled water, and incubated with tetramethylbenzine for 20 min. The reaction was stopped by adding 1 n H 2 SO 4 . Peroxidase activity was determined by measuring the OD at 450 nm using a Micro-Elisa reader. The purified human recombinant FasL produced in Pichia pastoris was used as a standard.
Mixed lymphocyte reaction assay
Mononuclear cells were separated from the peripheral blood of a BMT recipient, an HLA-identical sibling donor, and three unrelated volunteers. Stimulator cells were prepared by incubating a part of the mononuclear cells with mitomycin C at a concentration of 25 g/ml at 37°C for 30 min and adjusted to 7.5 × 10 5 cells/ml in RPMI containing 10% albumin. The remaining mononuclear cells were adjusted to 5.0 × 10 5 cells/ml in the same medium as responder cells. One 100 l aliquots of responder and stimulator cell suspensions were mixed together in a 96-well plate and incubated at 37°C for 6 days in triplicate. Subsequently, supernatant from one of the triplicate cultures was subjected to the ELISA for FasL. The remaining two were incubated with 3 H-thymidine at 37°C for 18 h and the levels of allogeneic stimulation were estimated by the mean radioactivities and described as counts per minute (c.p.m.).
Statistical analysis
The results are described as mean Ϯ standard deviation. Statistical comparison between groups was performed using the Mann-Whitney U test. The correlation between thymidine uptake and sFasL levels was analyzed by the line regression analysis.
Results
Soluble FasL levels in BMT recipients
The sFasL levels were examined by ELISA at several points after BMT. As shown in Figure 1 , serum sFasL was suppressed to an almost undetectable level along with myelosuppression after BMT, and subsequently increased following engraftment of the donor hematopoietic cells. Between the 21st and the 100th day after BMT, the sFasL levels of sera obtained in patients with and without aGVHD were 316.5 Ϯ 109.8 pg/ml and 66.1 Ϯ 60.2 pg/ml, respectively (Table 1) . A significant difference was demonstrated between the groups (P Ͻ 0.001). In all recipients who developed aGVHD, the serum sFasL levels increased to over 150 pg/ml simultaneously with the symptoms of aGVHD, except for two with a persistent low serum sFasL level, whose tissue damage was restricted to the intestine. The serum sFasL decreased after the resolution of the symptoms of aGVHD. The clinical severity of aGVHD did not correlate with the serum sFasL level. We observed no significant differences in sFasL levels between grade I aGVHD patients and grades II-IV aGVHD patients. To rule out the possibility that the elevated sFasL level only reflected the increased number of peripheral lymphocytes, the sFasL level was corrected by dividing the levels by the number of peripheral lymphocytes. The corrected sFasL levels were also higher at the points with aGVHD than without aGVHD (0.48 Ϯ 0.46 vs 0.18 Ϯ 0.15, P = 0.007) ( Table 1) . We observed a tendency toward higher serum sFasL level in patients with elevated serum C-reactive protein (156.4 Ϯ 161.0 vs 77.8 Ϯ 71.9, P = 0.14); however, the serum sFasL was not higher in patients with documented infections (one with invasive pulmonary aspergillosis and one with Staphylococcal bacteremia). The peak sFasL Table 2 Peak soluble Fas ligand levels in various groups Standard-risk group includes acute leukemia in first complete remission, CML in first chronic phase, SAA and MDS. High-risk group includes the remainder. AML = acute myeloblastic leukemia; ALL = acute lymphoblastic leukemia; CML = chronic myelogenous leukemia; SAA = severe aplastic anemia, MDS = myelodysplastic syndrome; TBI = total body irradiation; NS = not significant. levels were not affected by the underlying diseases, risk groups, use of total body irradiation or age (Table 2) .
Mixed lymphocyte reaction assay
Responder and stimulator cells were prepared from a BMT recipient, an HLA-identical sibling donor and three unrelated volunteers. Each of the responder lymphocytes was cultured in triplicate with each of the stimulator lymphocytes, including the responder cells themselves. The sFasL levels in the supernatants were measured in one of the triplicate. The levels of allogeneic stimulation were estimated by radioactive thymidine uptake into replicating DNA in the remaining two of the triplicate. As shown in Figure 2 the levels of thymidine uptake were low (2232.1 Ϯ 1443.9 c.p.m.) in cultures where the responder cells were stimulated by cells obtained from the same individual or the HLA-identical sibling. The sFasL levels in the supernatants were below 200 pg/ml in those cultures (92.0 Ϯ 32.1 pg/ml). In contrast, the levels of thymidine uptake and sFasL were much higher in cultures where the responder cells were stimulated by cells obtained from unrelated persons (31776.3 Ϯ 11885.8 c.p.m. and 399.9 Ϯ 160.4 pg/ml, respectively). The difference in the thymidine uptake and the sFasL levels between the two groups were statistically significant (P Ͻ 0.001). The sFasL levels showed a good correlation with the levels of thymidine uptake (r 2 = 0.88). These findings suggested that the allogeneic stimulation activates lymphocytes, resulting in the increased release of sFasL.
Discussion
In the present study, we demonstrated that the serum sFasL was suppressed during myelosuppression induced by the preparative regimen and increased with hematopoietic recovery after BMT. We also found that the serum sFasL levels were higher in patients with aGVHD than in those without aGVHD and that sFasL increased simultaneously with the symptoms of aGVHD. The serum sFasL level was not elevated in patients with documented infections. In vitro data by mixed lymphocyte reaction assay supported the idea that sFasL is released from lymphocytes triggered by allogeneic stimulation.
There have been reports describing the involvement of the Fas/FasL system in the pathogenesis of aGVHD. [5] [6] [7] Baker et al 5 showed in the murine GVHD model that recipients of allogeneic FasL-defective donor T cells exhibited only minimal signs of hepatic and cutaneous GVHD pathology, although they underwent severe GVHD-associated cachexia. In contrast, a metalloproteinase inhibitor, which blocks the release of both TNF␣ and FasL from the cell surface, 7 could almost completely abolish the GVHD-associated pathologies in the liver, intestine and hematopoietic tissues. 7 Considering these results together, Hattori et al 7 hypothesized that the Fas/FasL system might contribute mainly to the development of cutaneous and hepatic GVHD, and intestinal GVHD might be predominantly mediated by TNF␣. They showed in a recent report that intestinal GVHD lesion was improved by anti-TNF␣ but not anti-FasL monoclonal antibody. 11 In the present study, the serum sFasL in two patients, who had only an intestinal symptom of aGVHD, remained at a low level. These findings support this hypothesis although a large number of patients should be examined further to establish a definitive conclusion.
Three effector pathways, perforin/granzyme pathway, the Fas/FasL system and secreted molecules such as TNF␣ and ␥IFN, have been described for cytotoxic T lymphocytes. Murine models proved the importance of all these pathways in aGVHD. [5] [6] [7] 11 The serum sFasL level did not correlate with the severity of aGVHD, which also suggests that other pathways are involved in the development of aGVHD. It has been shown that the TNF␣ and the soluble interleukin-2 receptor (IL2-R) also increase in sera of BMT recipients with aGVHD. 12, 13 They begin to increase just after BMT and precede the occurrence of aGVHD. In contrast, the sFasL level rises almost simultaneously with the onset of aGVHD. Thus, the TNF␣ and the soluble IL-2R might be involved in both the inductive and effector phases of aGVHD, while the Fas/FasL system might contribute only to the effector phase. To predict the development of aGVHD, soluble TNF␣ and IL-2R are more useful than sFasL.
We have not determined whether the increase in sFasL resulted from the accelerated generation of the molecule or the activation of the cleavage from the membrane. The former is likely, because it has been shown that the expression of FasL transcripts is induced by T cell receptor engagement. 14 In addition, an increase in the percentage of CD8 + cells which express FasL in patients with aGVHD has been demonstrated. 15 The relationship between the Fas/FasL system and the development of aGVHD is complex. Activated Fas/FasL system may be responsible for the tissue damage associated with aGVHD. On the other hand, the Fas/FasL system may contribute to the elimination of allo-reactive donor T cells, resulting in the inhibition of aGVHD. Considering the results of murine BMT models, the Fas/FasL system seems likely to contribute to the acceleration of aGVHD. [5] [6] [7] The biological role of sFasL is still unknown. Previously, sFasL itself had been considered to induce tissue damages. 10 However, Tanaka et al 16 showed, in a recent paper, that sFasL is less effective than membranebound FasL (mFasL) in inducing apotosis and, furthermore, inhibits cytotoxicity of the mFasL. The increase in serum FasL may be produced as a modulator of mFasL. The increased sFasL in sera might rather block the tissue damage induced by the mFasL on activated lymphocytes. Anyway, the increase in serum sFasL level during aGVHD may reflect the activation of the Fas/FasL system. Some new prophylactic and therapeutic approaches for aGVHD have been investigated based on the molecular mechanism of the pathogenesis of aGVHD. 17, 18 We presented here the possible clinical importance of the Fas/FasL system on the development of tissue damage associated with aGVHD. Novel therapeutic agents to block the Fas/FasL system such as anti-FasL antibodies or FasFc (chimeric protein of Fas and the Fc region of the immunoglobulin heavy chain), 19 are expected to be applied to clinical BMT.
